STOK Stoke Therapeutics Inc
831
$11.53
$0.05
(0.44%)
| Watchers | 831 |
| 52-Wk Low | $3.35 |
| 52-Wk High | $16.40 |
| Market Cap | $598.34M |
| Volume | 6,745.00 |
| 52-Wk High | $16.40 |
| 52-Wk Low | $3.35 |
Analyst Expectations For Stoke Therapeutics's FutureBenzinga • 7 days ago
Latest Ratings for STOK
DateFirmActionFromTo Jan 2022JefferiesInitiates Coverage OnBuy Dec 2021B of A SecuritiesInitiates Coverage OnBuy Nov 2021JP MorganUpgradesNeutralOverweight
View More...
Share to Feed
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
Investors eyeing a purchase of Stoke Therapeutics Inc (STOK) stock, but cautious about paying the going market price of 12.82/share, might benefit from considering selling puts among the...
Stoke Therapeutics (NASDAQ:STOK - Get Free Report)s stock had its "overweight" rating reiterated by stock analysts at Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga...
Latest Ratings for STOK
DateFirmActionFromTo Jan 2022JefferiesInitiates Coverage OnBuy Dec 2021B of A SecuritiesInitiates Coverage OnBuy Nov 2021JP MorganUpgradesNeutralOverweight
View More...
Leerink Partners analyst Rudy Li has maintained their bullish stance on STOK stock, giving a Buy rating on March 26. Rudy Li has given his Buy rati...
Stoke Therapeutics (NASDAQ:STOK) stock soared by 73% following the report of updated data from a Phase 1/2 study of its STK-001, a drug for treatin...